Effects of Atomoxetine in Individuals with Attention-Deficit/Hyperactivity Disorder and Low-Functioning Autism Spectrum Disorder
| Autor: | Tuba Mutluer, Nahit Motavalli Mukaddes, Mustafa Deniz Tutkunkardaş, Ayse Kilincaslan, Basak Pasabeyoglu |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Male
medicine.medical_specialty Pediatrics Time Factors Adolescent Autism Spectrum Disorder Atomoxetine Hydrochloride Irritability 03 medical and health sciences 0302 clinical medicine mental disorders Intellectual disability medicine Humans Attention deficit hyperactivity disorder 0501 psychology and cognitive sciences Pharmacology (medical) Spectrum disorder Child Psychiatry Retrospective Studies Psychiatric Status Rating Scales Adrenergic Uptake Inhibitors 05 social sciences Atomoxetine medicine.disease Psychiatry and Mental health Treatment Outcome Attention Deficit Disorder with Hyperactivity Autism spectrum disorder Pediatrics Perinatology and Child Health Autism Female medicine.symptom Psychology 030217 neurology & neurosurgery 050104 developmental & child psychology Atomoxetine hydrochloride medicine.drug |
| Zdroj: | Journal of Child and Adolescent Psychopharmacology. 26:798-806 |
| ISSN: | 1557-8992 1044-5463 |
| DOI: | 10.1089/cap.2015.0179 |
| Popis: | This naturalistic, retrospective study investigated the effects of atomoxetine (ATX) on attention-deficit/hyperactivity disorder (ADHD) symptoms and autistic features in children with autism spectrum disorders (ASDs) and intellectual disability (ID).Participants (n = 37, age range 6-17 years, mean: 10.16 ± 3.60) were assessed at baseline, 4th and 12th weeks using Clinical Global Impressions (CGI) scales, DSM-IV-based ADHD-rating scale (ADHD-RS), and amended Turkish version of Aberrant Behavior Checklist (ABC). The primary outcome measure was a treatment response defined by a CGI-improvement score of 1 or 2 together with a decrease of at least 25% in the parent-rated ADHD-RS total score at the end of 12th week.Five patients (13.5%) stopped medication at 4 weeks due to ineffectivity (2) and intolerable side effects (increased motor activity and talkativeness [n = 1], irritability [n = 2], temper outbursts [n = 2], and increased blood pressure [n = 1]). Sixteen patients (43.2%) were judged to be responders according to primary outcome measure. Improvement rate on CGI scale was 48.8%. On ADHD-RS, there were significant reductions between baseline and 4th week and between baseline and 12th week in both hyperactivity and inattention, and between baseline and 12th week in impulsivity scores. Decrease was significant in hyperactivity and social withdrawal subscales of the parent-reported ABC. Responders based on primary outcome measure were not significantly different from nonresponders in terms of sociodemographic features or clinical parameters, including intellectual, language, autism symptom, and ADHD symptom levels.In this chart review, ATX appears to be safe and effective for social withdrawal and ADHD symptoms in children with ASD and ID. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|